x
Corporate Summary

Gain Therapeutics is redefining drug discovery with its SEE-Tx™ target identification platform. By identifying and optimizing allosteric binding sites that have never before been targeted, Gain is unlocking new treatment options for difficult-to-treat disorders characterized by protein misfolding.

 

Presentations

 

Press Releases
  • Jan 18 ,2022

    - Neuroscience and Beyond: Harnessing Computational Technology and Allosteric Modulators to Drug the Undruggable -- 18th Annual WORLDSymposium –- AD/PD™ 2022 - BETHESDA, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that it will be hosting an R&D Day Event and...

    Read More >

  • Jan 06 ,2022

    BETHESDA, Md., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that Chief Executive Officer Eric Richman, will participate in the H.C. Wainwright Bioconnect Conference and invites investors to participate via webcast. Please see additional details below: H.C....

    Read More >

  • Dec 28 ,2021

    BETHESDA, Md., Dec. 28, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted in neurodegenerative diseases and lysosomal storage disorders, today announced the grant of an option to purchase 200,000 shares of the Gain’s common stock and of 200,000 restricted stock units of Gain’s common stock to Matthias Alder, its Chief Operating Officer. These...

    Read More >

 

MORE



Stock Information
GANX



Contact IR

Company

GAIN THERAPEUTICS INC.

4800 Hampden Ln, St 200
Bethesda, MD 20814,
United State

Phone: +1 301 500 1556

Investor Relations

LifeSci Advisors, LLC

Dan Ferry
1 International Place
14th Floor
Boston, MA 02110

Phone: +1 617-430-7576
This email address is being protected from spambots. You need JavaScript enabled to view it.

 

Alerts Sign Up

Form by ChronoForms - ChronoEngine.com